Expertise in
27
conditions

Dr. Dinesh Kapur

Hematology
Eastern Ct Hematology & Oncology
330 Washington St Ste 220, 
Norwich, CT 
Offers Telehealth
Expertise in
27
conditions
Eastern Ct Hematology & Oncology
330 Washington St Ste 220, 
Norwich, CT 

Overview

Dinesh Kapur is a Hematologist practicing medicine in Norwich, Connecticut.

Dr. Kapur is highly rated in 27 conditions, according to our data. His clinical expertise encompasses Monoclonal Gammopathy of Undetermined Significance (MGUS), Non-Hodgkin Lymphoma, Multiple Myeloma, and Acute Myeloblastic Leukemia without Maturation.

He is actively involved in clinical research, co-authoring 1 peer reviewed article and participating in 6 clinical trials.

Specialties

Hematology

Licenses

Internal Medicine in CT

Hospital Affiliations

Lawrence & Memorial Hospital
William W Backus Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health First
  • HMO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

Eastern Ct Hematology & Oncology
330 Washington St Ste 220, Norwich, CT 06360

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Randomized, Open Label Phase 2/3 Study Comparing Cobolimab + Dostarlimab + Docetaxel To Dostarlimab + Docetaxel To Docetaxel Alone In Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed On Prior Anti-PD-(L)1 Therapy And Chemotherapy (COSTAR Lung)
A Randomized, Open Label Phase 2/3 Study Comparing Cobolimab + Dostarlimab + Docetaxel To Dostarlimab + Docetaxel To Docetaxel Alone In Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed On Prior Anti-PD-(L)1 Therapy And Chemotherapy (COSTAR Lung)
Enrollment Status: Active_not_recruiting
Publish Date: July 01, 2026
Intervention Type: Biological, Drug
Study Drugs: Cobolimab, Dostarlimab, Docetaxel
Study Phase: Phase 2/Phase 3
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease Has Remained Stable or Responded to First-Line Platinum -Based Chemotherapy With Pembrolizumab for Stage IIIB/IIIC or IV Non-Small Cell Lung Cancer (ZEAL-1L)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease Has Remained Stable or Responded to First-Line Platinum -Based Chemotherapy With Pembrolizumab for Stage IIIB/IIIC or IV Non-Small Cell Lung Cancer (ZEAL-1L)
Enrollment Status: Completed
Publish Date: June 18, 2026
Intervention Type: Biological, Drug
Study Drugs: Niraparib, Pembrolizumab
Study Phase: Phase 3
A Randomized Phase 3 Multicenter Open-Label Study to Compare the Efficacy of TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
A Randomized Phase 3 Multicenter Open-Label Study to Compare the Efficacy of TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
Enrollment Status: Active_not_recruiting
Publish Date: March 30, 2026
Intervention Type: Drug
Study Drugs: TAK-788, Pemetrexed, Cisplatin, Carboplatin
Study Phase: Phase 3
An Observational Study Assessing the Clinical Effectiveness of VeriStrat and Validating Immunotherapy Tests in Subjects With Non-Small Cell Lung Cancer
An Observational Study Assessing the Clinical Effectiveness of VeriStrat and Validating Immunotherapy Tests in Subjects With Non-Small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 19, 2025
Double-blinded, Randomized, Adaptive Registrational Trial to Compare Effectiveness of Two Digital Software Medical Devices (Attune™ and Cerena™) as Interventions for Physical and Emotional Health in Adjunctive Oncology Treatment
Double-blinded, Randomized, Adaptive Registrational Trial to Compare Effectiveness of Two Digital Software Medical Devices (Attune™ and Cerena™) as Interventions for Physical and Emotional Health in Adjunctive Oncology Treatment
Enrollment Status: Terminated
Publish Date: September 13, 2022
Intervention Type: Device
Study Phase: Not Applicable
A Randomized, Multicenter, Double-blind, Placebo-controlled, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma
A Randomized, Multicenter, Double-blind, Placebo-controlled, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma
Enrollment Status: Completed
Publish Date: December 30, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 5 Less Clinical Trials

1 Total Publications

Type 1 Autoimmune Pancreatitis Unmasked by COVID-19 Vaccine.
Type 1 Autoimmune Pancreatitis Unmasked by COVID-19 Vaccine.
Journal: ACG case reports journal
Published: June 07, 2022
Similar Doctors
Expertise in
26
conditions
Expertise in
26
conditions
Referral may be required

Rhode Island Hospital

593 Eddy St, 
Providence, RI 
 (39.5 miles away)
401-444-5435
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Adam Olszewski is a Hematologist practicing medicine in Providence, Rhode Island. Dr. Olszewski is highly rated in 26 conditions, according to our data. His clinical expertise encompasses B-Cell Lymphoma, Marginal Zone Lymphoma (MZL), Non-Hodgkin Lymphoma, Splenectomy, and Bone Marrow Aspiration.

Expertise in
11
conditions
Expertise in
11
conditions
Referral may be required

UConn John Dempsey Hospital

263 Farmington Ave, 
Farmington, CT 
 (38.7 miles away)
860-679-2100
Languages Spoken:
English
See accepted insurances

Biree Andemariam is a Hematologist practicing medicine in Farmington, Connecticut. Dr. Andemariam is highly rated in 11 conditions, according to our data. Her clinical expertise encompasses Sickle Cell Disease, Hemoglobinopathy, Congenital Hemolytic Anemia, and Hemolytic Anemia.

Expertise in
24
conditions
Expertise in
24
conditions
Referral may be required

Yale New Haven Hospital

20 York St, 
New Haven, CT 
 (47.0 miles away)
203-200-4363
Languages Spoken:
English
See accepted insurances

Amer Zeidan is a Hematologist practicing medicine in New Haven, Connecticut. Dr. Zeidan is highly rated in 24 conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Leukemia, Bone Marrow Transplant, and Bone Marrow Aspiration.

Frequently Asked Questions about Dr. Dinesh Kapur

How do I make an appointment with Dr. Dinesh Kapur?

You can book an appointment with Dr. Dinesh Kapur by calling their office at 860-886-8362. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Dinesh Kapur a top-rated expert for Monoclonal Gammopathy of Undetermined Significance (MGUS)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Dinesh Kapur is classified as an Distinguished expert for Monoclonal Gammopathy of Undetermined Significance (MGUS), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Dinesh Kapur specialize in?

While Dr. Dinesh Kapur is a Hematology, they have specific expertise in Monoclonal Gammopathy of Undetermined Significance (MGUS), Non-Hodgkin Lymphoma, and Multiple Myeloma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Dinesh Kapur participate in research or clinical trials?

Yes. Dr. Dinesh Kapur has published 1 articles and abstracts on conditions like Monoclonal Gammopathy of Undetermined Significance (MGUS). You can view a list of Dr. Dinesh Kapur's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Dinesh Kapur accept my insurance?

Dr. Dinesh Kapur accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 860-886-8362 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kapur's expertise for a condition
ConditionClose
    View All 25 Advanced Conditions
    View All 50 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile